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Background. Most HIV-1 transmission in Africa occurs among HIV-1-discordant couples (one partner HIV-1 infected and one
uninfected) who are unaware of their discordant HIV-1 serostatus. Given the high HIV-1 incidence among HIV-1 discordant couples
and to assess efficacy of interventions for reducing HIV-1 transmission, HIV-1 discordant couples represent a critical target
population for HIV-1 prevention interventions and prevention trials. Substantial regional differences exist in HIV-1 prevalence in
Africa, but regional differences in HIV-1 discordance among African couples, has not previously been reported. Methodology/
Principal Findings. The Partners in Prevention HSV-2/HIV-1 Transmission Trial (‘‘Partners HSV-2 Study’’), the first large HIV-1
prevention trial in Africa involving HIV-1 discordant couples, completed enrollment inMay 2007. Partners HSV-2 Study recruitment
data from 12 sites from East and Southern Africa were used to assess HIV-1 discordance among couples accessing couples HIV-1
counseling and testing, and to correlate with enrollment of HIV-1 discordant couples. HIV-1 discordance at Partners HSV-2 Study
sites ranged from 8–31% of couples tested from the community. Across all study sites and, among all couples with one HIV-1
infected partner, almost half (49%) of couples were HIV-1 discordant. Site-specific monthly enrollment of HIV-1 discordant couples
into the clinical trial was not directly associated with prevalence of HIV-1 discordance, but was modestly correlated with national
HIV-1 counseling and testing rates and access to palliative care/basic health care (r= 0.74, p=0.09). Conclusions/Significance.
HIV-1 discordant couples are a critical target for HIV-1 prevention in Africa. In addition to community prevalence of HIV-1
discordance, national infrastructure for HIV-1 testing and healthcare delivery and effective community outreach strategies impact
recruitment of HIV-1 discordant couples into HIV-1 prevention trials.
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INTRODUCTION
Among the estimated 40 million people worldwide currently living
with HIV-1 infection, 65% reside in sub-Saharan Africa [1], with
heterosexual exposure as the primary mode of HIV transmission.
Prior studies have found high rates of HIV-1 transmission
occurring between HIV-discordant partners (where one partner
is HIV- infected and one is HIV-uninfected) who are often in
stable partnerships but unaware of both partner’s HIV-1 serostatus
[2–4]. Recent data from Uganda indicate that 83% of HIV-
infected men and 77% of HIV-infected women are or have been
married [5]. Furthermore, among HIV-1 infected married
persons, 75% of men and 96% of women report having had sex
only with their spouse [5–7]. HIV-1 counseling and testing
specifically adapted to couples including education about HIV-1
discordance rather than an individual-focused HIV-1 risk
assessment and counseling can help reduce HIV-1 transmission
[2,8,9]. This underscores that stable HIV-1-discordant African
couples are a critical target for counseling and testing and
evaluation of new prevention interventions.
Microbicides, vaccines, pre-exposure prophylaxis, male circum-
cision, HSV-2 suppression, and other interventions are currently
under evaluation to increase the range of public health tools for
HIV-1 prevention. Efficacy trials and public health implementa-
tion studies of these interventions will require tens of thousands of
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participants over the coming years. Prevention trials that recruit
and follow HIV-1 discordant couples are of particular importance
in evaluating interventions for reducing HIV-1 infectiousness
while also permitting evaluation of biologic and behavioral factors
in both the transmitting and susceptible host which modulate the
risk of HIV-1 transmission.
There are unique challenges to conducting clinical trials with
HIV-1-discordant couple cohorts. In particular, recruiting both
partners to undergo HIV-1 counseling and testing together is
difficult, as only 10–30% of persons in Africa who are tested for
HIV-1 come as a couple [10]. This is in part due to the reluctance
of men to be tested for HIV-1 in many parts of Africa, coupled
with assumptions that their partner’s HIV-1 status is the same as
theirs (which is referred to as ‘HIV-1 testing by proxy’). In
addition, VCT counselors typically trained in individual VCT
techniques are reluctant to engage in couples’ HIV-1 counseling
and testing (CHCT) due to additional time required, for CHCT,
skills needed for addressing other relationship issues that may be
raised, and concerns about as well as the risk of domestic violence,
abandonment or stigmatization if one but not both partners learn
that they are HIV-1-infected [11–14]. Importantly, many HIV-1
counselors and couples have myths, misperceptions, and denial
about HIV-1 discordance [9].
Between November 2004 and May 2007 we recruited a cohort
of 3408 HIV-1-discordant couples from 14 sites in eastern and
southern Africa into the Partners in Prevention HSV-2/HIV-1
Transmission Trial (‘‘Partners HSV-2 Study’’). Recruitment for
this trial provided a unique opportunity to evaluate the prevalence
of HIV-1 discordance in diverse African communities and identify
factors correlating with recruitment of HIV-1-discordant couples.
METHODS
The Partners HSV-2 Study is designed to assess the impact of HSV-
2 suppression with acyclovir (400 milligrams orally, twice daily)
compared to placebo in reducing HIV-1-transmission among
couples in which one partner is HIV-1/HSV-2 co-infected with a
CD4 count $250 and not eligible for antiretroviral initiation, and
their partner is HIV-1-uninfected (ClinicalTrials.gov ID #
NCT00194519) [15–17]. In May 2007, 14 clinical trial sites in 7
countries in Eastern and Southern Africa completed screening of
7863 HIV-1 discordant couples and enrollment of 3408 HIV-1-
discordant couples. Follow-up will continue through May 2008 to
evaluate the efficacy of herpes suppression on reducing HIV-1
transmission to the initially HIV-1 uninfected partner.
Partners HSV-2 Study sites
Twelve of 14 Partners HSV-2 Study clinical trial sites recruited
couples from the community; two sites (Kigali, Rwanda and
Lusaka, Zambia) recruited couples from existing cohorts of HIV-1
discordant couples and therefore are not included in this analysis.
Of the 12 sites, six are in Eastern Africa, including Nairobi, Thika,
Kisumu and Eldoret, Kenya; Kampala, Uganda; and Moshi/
Arusha, Tanzania; and six in Southern Africa, including Soweto,
Orange Farm and Gugulethu, South Africa; Ndola and Kitwe,
Zambia; and Gaborone, Botswana.
Partners HSV-2 Study recruitment methods
Couples HIV-1 Counseling and Testing (CHCT) All study
sites used CHCT as the initial entry point for identifying
discordant couples who could then be evaluated for study
eligibility. Over 1000 community-based and study site counselors
were trained through the Partners HSV-2 Study using a CDC,
NIMH, Liverpool School of Tropical Medicine standardized
CHCT curriculum that covered basic counseling methods, the
importance of HIV-1-discordance, review of HIV-1 risk issues for
couples and approaches to counseling couples testing concordant
HIV-1-positive, concordant HIV-1-negative or HIV-1-discordant.
Partners HSV-2 Study Community Recruitment Couples
were either recruited directly through community outreach from
the Partners HSV-2 Study clinic including methods similar to
those reported elsewhere [2,8,18,19], or indirectly through
training of hundreds of community counselors in CHCT skills
and collaboration with community voluntary counseling and
testing (VCT) centers, antenatal and HIV-1 clinics, non-
governmental organizations, and coupled with direct community
outreach efforts with street theatre, one-to-one peer outreach,
radio discussions, and other messages about CHCT in the
community. These multiple strategies led to referral of interested
HIV-1 discordant couples to the Partners HSV-2 Study clinics for
additional counseling about HIV-1 discordance and screening for
eligibility for the Partners HSV-2 Study.
CHCT and VCT Data Collection
Community-based CHCT HIV-1 testing data among couples was
obtained from the principal community VCT centers who referred
HIV-1-discordant couples to the Partners HSV-2 Study clinics and
from testing of couples of unknown HIV-1 status at the Partners
HSV-2 Study clinics. These data were collected at the Ndola and
Kitwe, Zambia study sites from July 2005 through April 2006. For
the remaining sites due to the additional coordination and efforts
involved in data collection from multiple referring VCT centers,
prescreening data was only collected between December 2006 and
April 2007.
Prescreening data were used to calculate HIV-1 discordance,
HIV-1 negative and HIV-1 positive concordance as a percentage of
the total number of couples tested at those sites during the data
collection time period and as a weighted regional HIV-1 discordance
rate across sites on a country-specific basis, regionally (Eastern and
Southern Africa) and across these 12 Partners HSV-2 Study sites.
As an indicator of the utilization of HIV-1 counseling and
testing and basic health care services in participating countries, we
used publicly accessible data from the United States President’s
Emergency Program For AIDS Relief (PEPFAR) [20]. We defined
the National HIV-1 Response Index (NHRI) as the sum of the
annual number of individuals receiving HIV-1 counseling and
testing and palliative and basic health care services (including TB/
HIV-1) accessed in a country normalized to the estimated number
of people living with HIV-1/AIDS (PLWHA).
RESULTS
Descriptive data for the 12 Partners HSV-2 Study sites
participating in community-based recruitment of HIV-1-discor-
dant couples are presented in Table 1. Study sites vary from high
population-density cities and associated townships to smaller rural
towns. Based on Partners HSV-2 Study prescreening data, the
prevalence of stable HIV-1-discordant partnerships ranged from 8
to 31% of total couples tested at each study site. Overall, Eastern
and Southern African sites reported 12% and 18% HIV-1
discordance, respectively, with 15% HIV-1 discordance found
across the whole study. Among all couples tested who had at least
one HIV-1 infected partner, the proportion of couples which were
HIV-1-discordant varied by study sites from 36-85% with an
overall rate of 49%.
Approximately, 51,900 couples were prescreened for HIV-1
serostatus by partnering collaborating VCT centers, clinics or at
the Partners HSV-2 Study clinics. From this large community
HIV-1 Discordance in Africa
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CHCT effort, 7863 HIV-1-discordant couples were referred to
Partners HSV-2 Study sites and screened for study eligibility, of
whom 4178 met study eligibility criteria; 3408 couples were
enrolled into the Partners HSV-2 Study. Thus, for each HIV-1-
discordant couple enrolled in the clinical trial, over 15 couples (site
range 4.4–42.1) were provided CHCT and learned their HIV-1
status and 1.9 HIV-1-discordant couples (site range 1.5–2.3) were
screened for study eligibility.
Despite HIV-1 discordance being more prevalent in Southern
Africa, the site-specific Partners HSV-2 Study monthly enrollment
rate was higher in Eastern compared to Southern African sites
(15.1 versus 11.2 couples/month, respectively). Overall, HIV-1
discordance rates among couples tested in the community were
not significantly correlated with site-specific monthly study
enrollment rates (correlation coefficient -0.64, p = 0.16). There
was a trend for an association between the country NHRI (Table 1)
and average monthly site-specific enrollment of HIV-1 discordant
couples into the Partners HSV-2 Study (correlation coeffi-
cient = 0.74, p = 0.09). Other PEPFAR-reported measures for
dissemination of HIV-1 prevention information, such as persons
accessing ABC (‘Abstinence, ’Be faithful and use Condoms’)
messages, as measured by PEPFAR, did not strongly correlate
with study enrollment (correlation coefficient = 0.32, p = 0.54, data
not shown).
DISCUSSION
HIV-1 discordance was highly prevalent in the 12 communities
from Eastern and Southern Africa that participated in this multi-
site clinical trial of HSV-2 suppression to prevent HIV-1
transmission within HIV-1 discordant couples. Overall, among
couples presenting for HIV-1 testing in which one partner was
infected with HIV-1, 49% were identified as HIV-1-discordant.
The prevalence of HIV-1 discordance has been documented
previously in several African countries including in Zambia [21],
Uganda [3], Kenya [22]. Significant regional differences in HIV-1
discordance have previously been reported among couples
identified in the cross-sectional Four Cities study [22]. Notably,
two sites, Ndola, Zambia and Kisumu, Kenya were included in
both the Partners HSV-2 Study and the Four Cities Study and
observed to have similar prevalence of HIV-1 discordance (12%
versus 13% in Ndola and 16% versus 23% in Kisumu) 10 years
apart and using different sampling methodologies. The continued
high prevalence of HIV-1 discordance in diverse African sites
underscores the public health importance of couples with HIV-1
discordant results for HIV-1 prevention. By facilitating CHCT
training for almost 1000 counselors and heightening community
awareness of HIV-1-discordance in 14 study sites located in seven
countries, the Partners HSV-2 Study has demonstrated the
feasibility of recruiting and counseling HIV-1 discordant couples
in diverse regions of Africa. Building capacity for CHCT, with
development of messages about testing as couples and the
importance of HIV-1 discordance in HIV-1 transmission, is an
important and sustainable public health initiative in Africa.
Interestingly, we found no statistically significant association
between Partners HSV-2 Study enrollment rates and prevalence of
HIV-1 discordance among couples in study site communities. We
did find a trend for an association between site-specific average
monthly study enrollment and the NHRI, a normalized measure
of testing and care services accessed in a country. While difficulties
in mobilizing men to be tested, HIV-1-associated stigma, and fears
associated with disclosure of HIV-1 status remain ongoing
challenges in recruiting HIV-discordant couples, the Partners
HSV-2 Study recruitment experience suggests that enrolling HIV-
1 discordant couples for a clinical trial is affected more by the
availability of HIV-1 counseling, testing and palliative and basic
healthcare services and support for HIV-infected persons than by
a high prevalence of HIV-1 discordance. Notably, levels of
community access to ‘‘ABCs’’ messages, as measured by PEPFAR,
did not have an association with enrollment of HIV-1-discordant
couples. This may arise from abstinence and condom use messages
being viewed as less relevant to stable couples.
HIV-1 prevention trials involving HIV-1 discordant couples can
be implemented in countries with less developed VCT infrastruc-
ture and lower HIV-1 testing rates. The community recruitment
strategy utilized in the Ndola and Kitwe, Zambia sites, based on a
model developed in Rwanda [2] and previously implemented in
Lusaka, Zambia[21], was associated with high rates of enrollment
despite relatively lower national levels of counseling and testing in
Zambia. However, local factors impact the effectiveness of specific
clinical trial recruitment strategies, and attempts to implement this
recruitment model in other Partners HSV-2 Study sites were less
successful than in Zambia. Furthermore, recruitment costs were
reduced if referrals were obtained from community VCTs.
In conclusion, HIV-1 discordant couples represent an important
target population for HIV-1 prevention, given the high rates of
HIV-1 transmission in couples that do not know or disclose their
HIV-1 status. HIV-1 discordant couples are also a valuable
population for clinical trials evaluating vaccines, microbicides and
other HIV-1 prevention interventions. Our findings suggest that
increased national access to HIV-1 counseling and testing services
and health care can facilitate identification of HIV-1 discordant
couples for prevention interventions and enrollment into HIV-1
prevention trials. In view of these public health benefits and the
importance of identifying new prevention strategies to reduce
HIV-1 transmission in Africa, it is of critical importance to
enhance community mobilization to encourage couples to be
tested for HIV-1 as couples rather than as individuals, expand
training of counselors in CHCT techniques and counseling
messages about HIV-1 discordance, and prioritize prevention for
HIV-1-discordant couples in Africa.
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